Covestro plastic enables medical device innovation

Polycarbonate lends durability, good aesthetics to disposable on-body drug delivery device

One of the fastest-growing segments in the pharmaceutical industry is biologic drugs. Derived from a microorganism, or plant or animal cells, biologics are often used to treat rheumatoid arthritis, cancer, diabetes and many other diseases. Biologics are injected or infused, which typically requires inconvenient visits to specialty healthcare facilities or painful self-injections for patients.

To solve these challenges, Enable Injections, Inc. (www.enableinjections.com), has developed a disposable on-body drug delivery device that allows patients to comfortably self-administer high-volume and/or high-viscosity therapeutics. Components of the Enable device are injection molded with polycarbonate materials from Covestro LLC.
The housing of the on-body device features Makrolon® Rx1805 polycarbonate in a purple tint. Bayblend® M850 XF PC+ABS blend in a white tint is featured on the transfer system, which allows the patient to easily transfer the biologic drug from its original container to the Enable on-body delivery device.

“Covestro supported Enable Injections every step of the way from selecting the right polycarbonate materials to in-house part testing and manufacturing support,” said Brian Faul, business development manager – Midwest region, Polycarbonates, Covestro LLC.
Makrolon® Rx1805 polycarbonate, a medical-grade resin often used to produce transparent parts for medical devices, offers several advantages for the device’s housing including:
• Acceptable for sterilization with high-energy radiation
• Biocompatible according to many ISO 10993-1 test requirements
• High viscosity
• High lipid resistance
Bayblend® M850 XF PC+ABS blend offers several benefits for the transfer system including:
• Biocompatible according to many ISO 10993-1 test requirements
• Good flowability
• Heat resistant up to 131°C (Vicat B/120)
• High dimensional accuracy, stability and toughness

“Biologic medicines are very sensitive and the materials selected for the delivery and transfer systems are of utmost importance for patient safety,” said Lauren Zetts, North America market manager, Medical and Consumer Products –Polycarbonates, Covestro LLC. “At Covestro we continuously strive to provide medical OEMs the materials they need to bring their devices to market, so naturally we’re gratified to be selected for this application, which is making such a positive impact on patients’ lives.”

Attendees at Medtec China 2018 on September 26-28 at Shanghai World Expo Exhibition & Convention Center can visit the company’s booth (T101) for more details about medical applications and materials from Covestro.

About Covestro:
With 2017 sales of EUR 14.1 billion, Covestro is among the world’s largest polymer companies. Business activities are focused on the manufacture of high-tech polymer materials and the development of innovative solutions for products used in many areas of daily life. The main segments served are the automotive, construction, wood processing and furniture, and electrical and electronics industries. Other sectors include sports and leisure, cosmetics, health and the chemical industry itself. Covestro has 30 production sites worldwide and employs approximately 16,200 people (calculated as full-time equivalents) at the end of 2017.

About Enable Injections:
Founded February 2010 by medical device industry veterans, Cincinnati, OH-based Enable Injections develops and manufactures wearable devices that allow easy, comfortable patient self-administration of large volume/high viscosity drugs for pharmaceutical and biotechnology industry investigational use. The Enable bodyworn injector utilizes any standard container closure system, including syringe or vial; automatically warms and can automatically mix lyophilized solutions.www.enableinjections.com.

Find more information at www.covestro.com

Forward-looking statements
This news release may contain forward-looking statements based on current assumptions and forecasts made by Covestro AG. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Covestro’s public reports which are available at www.covestro.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.